Pacer Advisors
PCVX icon

Pacer Advisors’s Vaxcyte PCVX Stock Holding History

Pacer Advisors’s Portfolio PCVX Stock Details PCVX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$59K Buy
+1,015
New +$55.1K ﹤0.01% 1999
2024
Q3 		– Sell
-539
Closed -$40.7K – 2658
2024
Q2 		$40.7K Sell
539
-50
-8% -$3.4K ﹤0.01% 3265
2024
Q1 		$40.2K Buy
+589
New +$40.8K ﹤0.01% 3259
2021
Q2 		– Sell
-2,122
Closed -$42K – 1510
2021
Q1 		$42K Buy
2,122
+850
+67% +$21.4K ﹤0.01% 1459
2020
Q4 		$34K Buy
+1,272
New +$47.3K ﹤0.01% 1452

Other funds holding PCVX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Pacer Advisors's PCVX Position: Q2 2026 in Review

Pacer Advisors opened a new position in Vaxcyte (PCVX) in Q2 2026: 1,015 shares worth $59K. The stake represents ﹤0.01% of the portfolio and ranks #1999 among its holdings. This is a return to the name: Pacer Advisors previously reported a position in PCVX as recently as Q2 2024.

Pacer Advisors first reported a position in PCVX in Q4 2020 and has held it in 5 quarters since. 332 funds tracked by Wall St. Rank hold PCVX as of Q2 2026.

  • Pacer Advisors held 1,015 shares of Vaxcyte worth $59K as of Q2 2026.
  • Vaxcyte was a new Pacer Advisors position in Q2 2026.
  • Vaxcyte made up ﹤0.01% of Pacer Advisors's portfolio in Q2 2026, its #1999 holding.
  • Pacer Advisors first reported a position in Vaxcyte in Q4 2020 and has held it in 5 quarters since.
  • 332 funds tracked by Wall St. Rank held Vaxcyte as of Q2 2026.

Based on Pacer Advisors's 13F filing for Q2 2026, filed 13 Aug 2026.